Molecure S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOC.WA research report →
About the company
Operating as a biopharmaceutical firm in Poland, Molecure S. A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions.
- CEO
- Marcin Jan Szumowski
- IPO
- 2018
- Employees
- 102
- HQ
- Warsaw, PL
Price Chart
- Market Cap
- $112.51M
- P/E
- -7.65
- P/S
- 37.29
- P/B
- 1.10
- EV/EBITDA
- -6.00
- Div Yield
- 0.00%
- Gross Margin
- -28.32%
- Op Margin
- -581.74%
- Net Margin
- -482.57%
- ROE
- -15.59%
- ROIC
- -16.46%
- Revenue
- $0 · -100.00%
- Net Income
- $-15,688,578 · 49.86%
- EPS
- $-0.77 · 50.32%
- Op Income
- $-22,035,765
- FCF YoY
- 75.96%
- 52W High
- $9.06
- 52W Low
- $4.98
- 50D MA
- $5.57
- 200D MA
- $6.58
- Beta
- 1.03
- Avg Volume
- 57.35K
Get TickerSpark's AI analysis on MOC.WA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MOC.WA coverage
Recent articles, reports, and earnings notes.
No research on MOC.WA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MOC.WA report →Similar companies
Peers in the same neighborhood.